Shield Therapeutics plc (SHIEF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shield Therapeutics plc (SHIEF) with AI Score 62/100 (Hold). Shield Therapeutics plc is a specialty pharmaceutical company focused on addressing unmet medical needs through the development and commercialization of innovative therapies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Shield Therapeutics plc (SHIEF) Healthcare & Pipeline Overview
Shield Therapeutics plc is a specialty pharmaceutical company developing and commercializing therapies for iron deficiency and hyperphosphatemia. Its primary product, Accrufer/Feraccru, offers a non-salt-based oral treatment for iron deficiency, positioning the company within the specialty drug market focused on unmet medical needs.
Investment Thesis
Shield Therapeutics presents an investment opportunity within the specialty pharmaceutical sector, driven by its focus on iron deficiency and hyperphosphatemia. Accrufer/Feraccru's market penetration and potential for increased adoption represent a key value driver. The successful commercialization of PT20, following positive Phase II results, could further enhance the company's revenue streams. However, the company's negative P/E ratio of -5.26 and a negative profit margin of -51.2% indicate financial challenges. Upcoming catalysts include potential regulatory approvals and expansion of Accrufer/Feraccru's market presence. Potential risks include competition from existing iron deficiency treatments and the successful completion of clinical trials for PT20.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.15 billion reflects the company's current valuation in the specialty pharmaceutical market.
- Gross margin of 44.6% indicates the profitability of Shield Therapeutics' core product, Accrufer/Feraccru.
- Negative P/E ratio of -5.26 suggests the company is currently not profitable.
- Profit margin of -51.2% highlights the challenges in achieving profitability despite a positive gross margin.
- Beta of 1.91 indicates higher volatility compared to the overall market, reflecting the risks associated with a specialty pharmaceutical company.
Competitors & Peers
Strengths
- Proprietary non-salt based oral iron therapy (Accrufer/Feraccru).
- Phase II clinical data for PT20 in hyperphosphatemia.
- Focus on unmet medical needs.
- Experienced management team.
Weaknesses
- Negative profitability and high operating expenses.
- Reliance on a limited number of products.
- Limited commercial infrastructure.
- Dependence on partnerships for market access.
Catalysts
- Ongoing: Expansion of Accrufer/Feraccru market share through targeted marketing and geographic expansion.
- Upcoming: Potential regulatory approvals for Accrufer/Feraccru in new markets.
- Upcoming: Positive Phase III trial results for PT20 in hyperphosphatemia.
- Ongoing: Strategic partnerships and licensing agreements to expand product portfolio.
- Ongoing: Development of new formulations and indications for existing products.
Risks
- Ongoing: Competition from existing iron deficiency treatments and generic alternatives.
- Potential: Regulatory hurdles and delays in obtaining approvals for new products.
- Potential: Patent expiration and generic competition for Accrufer/Feraccru.
- Potential: Economic downturn and reduced healthcare spending impacting sales.
- Ongoing: Negative profitability and high operating expenses.
Growth Opportunities
- Expansion of Accrufer/Feraccru Market Share: The market for iron deficiency treatments is substantial, estimated at billions of dollars globally. Shield Therapeutics has the opportunity to increase its market share by expanding the reach of Accrufer/Feraccru through strategic partnerships, targeted marketing, and geographic expansion. The timeline for realizing this growth is ongoing, with continuous efforts to penetrate new markets and increase adoption among healthcare providers.
- Successful Commercialization of PT20: The successful development and commercialization of PT20 for the treatment of hyperphosphatemia in chronic kidney disease patients represents a significant growth opportunity. The market for phosphate binders is substantial, driven by the increasing prevalence of chronic kidney disease. Positive Phase III trial results and regulatory approvals are critical milestones for realizing this growth, with a potential timeline of 2-3 years for market entry.
- Strategic Partnerships and Licensing Agreements: Shield Therapeutics can leverage strategic partnerships and licensing agreements to expand its product portfolio and geographic reach. Collaborating with larger pharmaceutical companies or regional distributors can accelerate the commercialization of its products and access new markets. The timeline for securing such partnerships is ongoing, with continuous efforts to identify and pursue potential collaborations.
- Development of New Formulations and Indications: Shield Therapeutics can invest in the development of new formulations and indications for its existing products. This can extend the product lifecycle and address additional patient populations. For example, exploring new formulations of Accrufer/Feraccru or investigating its potential use in other indications could drive further growth. The timeline for developing new formulations and indications is typically 3-5 years.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, represents a significant growth opportunity for Shield Therapeutics. These markets have a large and growing population with increasing access to healthcare. Adapting its commercialization strategy to suit the specific needs of these markets is crucial for success. The timeline for geographic expansion is typically 2-3 years per market.
Opportunities
- Expansion of Accrufer/Feraccru market share.
- Successful commercialization of PT20.
- Strategic partnerships and licensing agreements.
- Geographic expansion into emerging markets.
Threats
- Competition from existing iron deficiency treatments.
- Regulatory hurdles and delays.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary non-salt based oral therapy for iron deficiency.
- Patent protection for Accrufer/Feraccru and PT20.
- Clinical data supporting the efficacy and safety of their products.
- Established relationships with healthcare providers and key opinion leaders.
About SHIEF
Founded in 2008 and based in Gateshead, United Kingdom, Shield Therapeutics plc is a specialty pharmaceutical company dedicated to the development and commercialization of clinical-stage pharmaceuticals that address unmet medical needs. The company's core focus is on iron deficiency and hyperphosphatemia. Its lead product, Accrufer/Feraccru, is a non-salt-based oral therapy designed for the treatment of iron deficiency with or without anemia in adults. This product represents a significant advancement in iron supplementation, offering a potentially more tolerable and effective alternative to traditional iron salts. Shield Therapeutics is actively engaged in expanding the market reach and adoption of Accrufer/Feraccru through strategic partnerships and targeted marketing initiatives. In addition to Accrufer/Feraccru, Shield Therapeutics is developing PT20, a novel iron-based phosphate binder. PT20 has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The development of PT20 underscores Shield Therapeutics' commitment to addressing critical medical needs in specific patient populations. The company operates with a team of 63 employees, focusing on research, development, and commercialization activities.
What They Do
- Develop and commercialize clinical-stage pharmaceuticals.
- Focus on unmet medical needs in specific therapeutic areas.
- Offer a non-salt based oral therapy for the treatment of iron deficiency.
- Develop a novel iron-based phosphate binder for hyperphosphatemia.
- Conduct clinical trials to evaluate the safety and efficacy of their products.
- Seek regulatory approvals for their products in various markets.
- Establish strategic partnerships to expand market reach.
Business Model
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through sales of Accrufer/Feraccru.
- Out-license or partner for commercialization in certain territories.
- Invest in research and development to expand product pipeline.
Industry Context
Shield Therapeutics operates within the specialty pharmaceutical industry, which is characterized by a focus on niche markets and specific medical needs. The market for iron deficiency treatments is substantial, driven by the prevalence of anemia and the limitations of existing therapies. The competitive landscape includes established pharmaceutical companies and generic drug manufacturers. Shield Therapeutics differentiates itself through its non-salt-based oral therapy, Accrufer/Feraccru, which offers potential advantages in terms of tolerability and efficacy. The company's focus on hyperphosphatemia also positions it within the chronic kidney disease market, which is expected to grow due to the increasing prevalence of kidney disorders.
Key Customers
- Adults with iron deficiency with or without anemia.
- Patients with chronic kidney disease and hyperphosphatemia.
- Healthcare providers who prescribe and administer their products.
- Pharmacies that dispense their medications.
Financials
Chart & Info
Shield Therapeutics plc (SHIEF) stock price: Price data unavailable
Latest News
No recent news available for SHIEF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHIEF.
Price Targets
Wall Street price target analysis for SHIEF.
MoonshotScore
What does this score mean?
The MoonshotScore rates SHIEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anders Lundstrom
CEO
Anders Lundstrom serves as the CEO of Shield Therapeutics plc, bringing extensive experience in the pharmaceutical industry. His background includes leadership roles in various pharmaceutical companies, with a focus on commercialization and market access. Lundstrom's expertise spans across multiple therapeutic areas, including gastroenterology and nephrology. He has a proven track record of driving revenue growth and expanding market share for pharmaceutical products.
Track Record: Under Anders Lundstrom's leadership, Shield Therapeutics has focused on expanding the market reach of Accrufer/Feraccru and advancing the development of PT20. Key milestones include securing regulatory approvals for Accrufer/Feraccru in new markets and completing Phase II clinical trials for PT20. Lundstrom has also overseen strategic partnerships to enhance the company's commercial capabilities.
SHIEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Shield Therapeutics plc may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, potentially increasing investment risk compared to companies listed on major exchanges like NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other companies may have limited operating history or financial resources.
- Delisting risk if the company fails to meet minimum requirements.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established business operations and product offerings.
- Presence of experienced management team.
- Positive clinical trial data for key products.
- Strategic partnerships with reputable organizations.
- Patent protection for core technologies.
What Investors Ask About Shield Therapeutics plc (SHIEF)
What does Shield Therapeutics plc do?
Shield Therapeutics plc is a specialty pharmaceutical company focused on developing and commercializing treatments for iron deficiency and hyperphosphatemia. Its lead product, Accrufer/Feraccru, is a non-salt-based oral therapy for iron deficiency, offering a potentially more tolerable alternative to traditional iron salts. The company is also developing PT20, an iron-based phosphate binder for hyperphosphatemia in chronic kidney disease patients. Shield Therapeutics aims to address unmet medical needs in these specific therapeutic areas through innovative pharmaceutical solutions.
What do analysts say about SHIEF stock?
AI analysis is currently pending for SHIEF. Generally, analysts will assess the company's financial performance, product pipeline, and market opportunities to determine a fair valuation. Key metrics include revenue growth, profitability, and the potential for Accrufer/Feraccru and PT20 to generate significant revenue streams. The competitive landscape and regulatory environment are also important factors in analyst evaluations. Analyst consensus will reflect the overall sentiment regarding the company's prospects and potential for future growth.
What are the main risks for SHIEF?
The main risks for Shield Therapeutics include competition from established iron deficiency treatments, potential regulatory hurdles and delays, and the risk of patent expiration and generic competition. The company's negative profitability and high operating expenses also pose a significant risk. Furthermore, economic downturns and reduced healthcare spending could negatively impact sales. Successful clinical trials and regulatory approvals for PT20 are critical, and any setbacks in these areas could adversely affect the company's prospects.
What revenue streams does Shield Therapeutics plc have in healthcare?
Currently, Shield Therapeutics plc primarily generates revenue from the sales of Accrufer/Feraccru, its non-salt-based oral therapy for the treatment of iron deficiency. Revenue streams are dependent on market penetration, sales volume, and geographic expansion. The company is actively working to increase adoption of Accrufer/Feraccru among healthcare providers and patients. If PT20 receives regulatory approval, it will create a second revenue stream focused on the treatment of hyperphosphatemia in patients with chronic kidney disease. Strategic partnerships and licensing agreements could also generate additional revenue.
How does Shield Therapeutics plc manage patent expiration risks?
Shield Therapeutics plc manages patent expiration risks through a combination of strategies, including extending patent protection through new formulations and indications, and developing a pipeline of new products. The company actively seeks to protect its intellectual property and maintain a competitive advantage. Lifecycle management strategies are employed to maximize the value of existing products and mitigate the impact of patent expirations. The development of PT20 represents a diversification strategy to reduce reliance on Accrufer/Feraccru and create new revenue streams.
What are the key factors to evaluate for SHIEF?
Shield Therapeutics plc (SHIEF) currently holds an AI score of 62/100, indicating moderate score. Key strength: Proprietary non-salt based oral iron therapy (Accrufer/Feraccru).. Primary risk to monitor: Ongoing: Competition from existing iron deficiency treatments and generic alternatives.. This is not financial advice.
How frequently does SHIEF data refresh on this page?
SHIEF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SHIEF's recent stock price performance?
Recent price movement in Shield Therapeutics plc (SHIEF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary non-salt based oral iron therapy (Accrufer/Feraccru).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.